Furthermore, using a novel cyclic peptide inhibitor that binds to the ADAM8 disintegrin domain, they demonstrated a profound reduction in tumor burden and metastasis in orthotopic xenograft and KrasG12D transgenic mouse models of pancreatic cancer. This evidence concerns the gene ADAM8 and neoplasm.